Meet our Trustee: Professor John Marshall MBE
Prof John Marshall is the Frost Professor of Ophthalmology at the Institute of Ophthalmology at University College London.
Search
Search results
Does gene therapy always have to be gene-specific?
Early 2020 marked an important milestone for the Retina UK community, when the first person with an inherited retinal condition received NHS treatment to potentially slow or even stop the progression of their sight loss.
Applying for research funding
We provide funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease.
Exciting developments for new treatment research
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Manchester Half Marathon
Join 15,000 people for an Old Trafford start and finish.
Jurassic Coast Challenge
Join 2,000 adventurers of all experience levels & ages and walk, jog or run 25, 50 or 100km of the spectacular Jurassic Coast – a World Heritage Site.
South Coast Challenge
Walk, jog or run 100km, 50km or 25km and take on some of England’s finest scenery along the famous South Downs Way National Trail.
Chiltern 50 Challenge
This ‘end of season’ 50km looped route covers some of the best of the Chilterns countryside. You can walk, jog, or run along historic trails and over rolling hills. A half distance 25km challenge is also available.
Information for employers
If you are considering employing someone with inherited sight loss, or have an employee recently been diagnosed with the condition, you will need to take steps to ensure that you treat them fairly and that they can work safely and effectively.
Webinar: DNA and RNA tools for Stargardt’s Disease
Elena Piotter, a PhD student working in Robert MacLaren’s group in the Nuffield Laboratory of Ophthalmology at the University of Oxford, is currently researching DNA and RNA base editing tools aiming to correct pathogenic mutations in ABCA4.